US2021283173A1PendingUtilityA1

Methods and compositions for extending lifespan

Assignee: LONGEVICA THERAPEUTICS INCPriority: Oct 19, 2016Filed: May 24, 2021Published: Sep 16, 2021
Est. expiryOct 19, 2036(~10.2 yrs left)· nominal 20-yr term from priority
A61K 33/14A23V 2250/032A61K 2300/00A61K 31/194A61K 31/216A61K 33/06A61K 31/733A61K 31/198A23L 33/105A23V 2250/5062A23V 2002/00A61K 45/06A23V 2250/21A23V 2250/161A61P 39/04
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for attenuating aging, of health maintenance, and/or treating, or delaying the onset of, an age-related condition or disorder, in a subject comprising administering to the subject an effective amount of (a) one or more compounds that sustain pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion and (b) one or more chelators. A further aspect of the invention is a composition comprising (a) and (b).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A dietary supplement or food or beverage product comprising:
 (a) one or more compounds that sustain the pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion; and   (b) one or more chelators.   
     
     
         2 . The dietary supplement or food or beverage product of  claim 1  wherein (a) is inulin. 
     
     
         3 . The dietary supplement or food or beverage product of  claim 1  wherein (a) is an agonist of nuclear receptors that activate xenobiotic metabolism. 
     
     
         4 . The dietary supplement or food or beverage product of  claim 3  wherein the agonist of nuclear receptors that activate xenobiotic metabolism is selected from the group consisting of constitutive androstane receptor (CAR) agonists, pregnane X receptor (PXR) agonists, or a peroxisome proliferator-activated receptor α (PPARα) agonist. 
     
     
         5 . The dietary supplement or food or beverage product of  claim 3  wherein the agonist of nuclear receptors that activate xenobiotic metabolism is clofibrate. 
     
     
         6 . The dietary supplement or food or beverage product of any of  claims 1 - 5  wherein (b) is diethylenetriaminepentaacetic acid (DTPA). 
     
     
         7 . A dietary supplement or food or beverage product comprising:
 (a) Inulin; and   (b) Citric acid.   
     
     
         8 . The dietary supplement or food or beverage product of  claim 7  further comprising magnesium or a magnesium salt. 
     
     
         9 . The dietary supplement or food or beverage product of  claim 7  or  8  comprising, per serving:
 (a) 5-10 grams of inulin; and 
 (b) 1-2 grams of citric acid. 
 
     
     
         10 . The dietary supplement or food or beverage product of  claim 9  further comprising 200-300 milligrams of magnesium or a magnesium salt per serving. 
     
     
         11 . The dietary supplement or food or beverage product of  claim 10  comprising 250 milligrams of magnesium or a magnesium salt per serving. 
     
     
         12 . A dietary supplement or food or beverage product comprising:
 (a) Inulin; and   (b) Lemon or lime extract, DTPA, EDTA, St. John's wort extract, Hyperforin,  Ginkgo bilogoba  extract, Ginkgolide A or B, vitamin C, Ascorbic acid 6-palmitate, Pantothenic acid (vitamin B-5), Niacinamide, Allicin (garlic), Lactobionate, Melatonin, Metformin, L-Dopa, extract  Mucuna  beans ( Mucuna  Dopa), L-Histidine, Quercetin, Curcumin, L-Glutamic acid, succinic acid, N-Acetil Cysteine, Green tea extract, Epigallocatechin-3-gallaye, Glutathione, Aspirin, Salicylate, Glycine, Resveratrol, Genistein, Garnosine, Rapamycin, Lipoic acid, or Taurine.   
     
     
         13 . The dietary supplement or food or beverage product of  claim 12  further comprising magnesium or a magnesium salt. 
     
     
         14 . A dietary supplement or food or beverage product comprising:
 (a) Inulin;   (b) St. John's wort extract, Hyperforin,  Ginkgo bilogoba  extract, or Ginkgolide A or B, Rapamycin; and   (c) Citric acid.   
     
     
         15 . The dietary supplement or food or beverage product of  claim 14  further comprising magnesium or a magnesium salt. 
     
     
         16 . The dietary supplement or food or beverage product of any of  claims 1 - 15 , wherein the dietary supplement or food or beverage product is:
 (a) yogurt;   (b) porridge;   (c) bread;   (d) baby food;   (e) a sports drink;   (f) an energy bar;   (g) chocolate.   
     
     
         17 . The dietary supplement of any of  claims 1 - 15  in the form of a tablet or capsule for oral ingestion. 
     
     
         18 . A method of attenuating aging, of health maintenance, and/or treating or delaying the onset of, an age-related condition or disorder, the method comprising administering to the subject an effective amount of:
 (a) one or more compounds that sustain the pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion; and   (b) one or more chelators.   
     
     
         19 . The method of  claim 18 , wherein the administration prolongs the lifespan of the subject relative to the lifespan of the subject in the absence of the administration. 
     
     
         20 . The method of  claim 18 , wherein the administration treats or delays the onset of the age-related disease in the subject relative to the subject in the absence of the administration. 
     
     
         21 . The method of any one of  claims 18 - 20  wherein (a) is inulin. 
     
     
         22 . The method of any one of  claims 18 - 20  wherein (a) is an agonist of nuclear receptors that activate xenobiotic metabolism. 
     
     
         23 . The method of  claim 22 , wherein the agonist of nuclear receptors that activate xenobiotic metabolism is selected from the group consisting of constitutive androstane receptor (CAR) agonists, pregnane X receptor (PXR) agonists, or a peroxisome proliferator-activated receptor α (PPARα) agonist. 
     
     
         24 . The method of  claim 22  wherein the agonist of nuclear receptors that activate xenobiotic metabolism is clofibrate. 
     
     
         25 . The method of any of  claims 18 - 24  wherein (b) is:
 Lemon or lime extract, DTPA, EDTA, St. John's wort extract, Hyperforin,  Ginkgo bilogoba  extract, Ginkgolide A or B, vitamin C, Ascorbic acid 6-palmitate, Pantothenic acid (vitamin B-5), Niacinamide, Allicin (garlic), Lactobionate, Melatonin, Metformin, L-Dopa, extract  Mucuna  beans ( Mucuna  Dopa), L-Histidine, Quercetin, Curcumin, L-Glutamic acid, succinic acid, N-Acetil Cysteine, Green tea extract, Epigallocatechin-3-gallaye, Glutathione, Aspirin, Salicylate, Glycine, Resveratrol, Genistein, Garnosine, Rapamycin, Lipoic acid, or Taurine. 
 
     
     
         26 . The method of any of  claims 18 - 25  wherein (b) is diethylenetriaminepentaacetic acid (DTPA). 
     
     
         27 . The method of any of  claims 18 - 26  wherein the administration prolongs the lifespan of the subject more than the individual effect of the administration of either (a) or (b). 
     
     
         28 . The method of any of  claims 18 - 27  wherein the administration prolongs the lifespan of the subject more than the sum of the individual effect of the administration of (a) and (b). 
     
     
         29 . The method of any one of  claims 18 - 28  further comprising administering to the subject an effective amount of one or more compound selected from the group consisting of:
 (a) a COX inhibitor; 
 (b) an antiparasitic agent; 
 (c) an acetylcholinesterase inhibitor; 
 (d) an adenosine receptor antagonist; 
 (e) a selective estrogen receptor modulator. 
 
     
     
         30 . The method of any one of  claims 18 - 29  further comprising administering to the subject an effective amount of a magnesium salt. 
     
     
         31 . The method of  claim 30  wherein the magnesium salt is Magnesium hydroxide, Magnesium acetate, or magnesium chloride. 
     
     
         32 . The method of any one of  claims 18 - 31  further comprising administering to the subject an effective amount of citric acid.

Join the waitlist — get patent alerts

Track US2021283173A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.